CYTO - Altamira Therapeutics Average Forecast Price

Altamira Therapeutics (CYTO) focuses on the development of innovative inhalation systems and RNA therapies, maintaining offices in the US and Switzerland. Currently, its nasal platforms are undergoing the pre-sale licensing stage, while the expansion of the development portfolio is driving up research expenses. This chart reflects an asset value of 5.32, with the business operating on the principles of bioethics and sustainable waste disposal.

CYTO - Altamira Therapeutics Price Target Chart over the range 07/04/2022 - 01/04/2025

Analytical breakdowns for Altamira Therapeutics (CYTO)

- market price and analyst price targets:

Stock Quotes altamiratherapeutics.com|CYTO - Consensus Target

- market capitalization statistics:

Market Value Auris Medical|CYTO - Real Price to Acquire Entire Company

- shareholders' equity book value data:

Book Price of a Share Altamira Therapeutics|CYTO - Company Book Value|Market-to-Book Ratio altamiratherapeutics.com|CYTO - Aggregate Company Assets

- business debt structure and liquidity details:

Aggregate Debt to Equity Altamira Therapeutics|CYTO - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital altamiratherapeutics.com|CYTO - Company Aggregate Debts|Debts to Book Capitalization Auris Medical|CYTO - Company Long-Term Debt|Company Short-Term Loans and Borrowings Altamira Therapeutics|Quick Liquidity Indicator altamiratherapeutics.com

- earnings and market ratios statistics:

CYTO - Net Profit|Projected Future Earnings Altamira Therapeutics|CYTO - Price to Earnings Ratio|Future Price to Earnings Multiple altamiratherapeutics.com|CYTO - Price/Earnings to Growth Ratio|Company Value to EBITDA Auris Medical|CYTO - Operating profit before deduction of amortization|Earnings per share for the last four quarters Altamira Therapeutics|CYTO - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months altamiratherapeutics.com|CYTO - Earnings growth in current year|Expected net earnings per share growth next year Altamira Therapeutics

General company analysis:CYTO Altamira Therapeutics Ltd

Flagship merchandise of Altamira Therapeutics Ltd.

Altamira Therapeutics' development of the OligoPhore platform for RNA drug delivery and its pursuit of partnerships with pharmaceutical behemoths define the business's capitalization potential. The dynamics of the consensus estimated value reflect the weighted average view of investment banks on asset valuation, allowing investors to contrast market noise with the issuer's actual ability to generate cash flow and assess solvency risks through the target price trend.

Competitors of Altamira Therapeutics